Biocytogen, BioCopy sign licensing agreement for TCR-mimic antibodies
BioCopy will get access to fully human TCR-mimic antibodies targeting an antigen generated by Biocytogen’s unique RenTCR-mimic mice,…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
07 May 24
BioCopy will get access to fully human TCR-mimic antibodies targeting an antigen generated by Biocytogen’s unique RenTCR-mimic mice,…
07 May 24
Mycophenolate mofetil functions as an antimetabolite immunosuppressant to protect a transplanted organ from the body's immune system to…
07 May 24
Duravyu, previously known as EYP-1901, is being developed as a potential paradigm-altering therapy for individuals with VEGF-mediated retinal…
07 May 24
Under the deal, Gossamer Bio and Chiesi Group will develop and commercialise Seralutinib in PAH, PH-ILD & other…
07 May 24
For development and commercialization of a new and unique formulation of liquid stable glucagon for use in a…
07 May 24
In Q4 2023, Cellectis received an initial payment of $105m from AstraZeneca, which comprised a $25m upfront cash…
06 May 24
Zokinvy is a disease-modifying agent that blocks the accumulation of defective progerin and progerin-like proteins that cause premature…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
06 May 24
The results showed that BI 764524 was well received upon intravitreal administration of both single and multiple doses…
03 May 24
Mariana Oncology is a preclinical-stage biotechnology company focused on developing novel radioligand therapies (RLTs) to treat cancers, and…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 May 24
As per the pre-agreed terms of the JV, Bayer has secured full ownership of the entity which was…